medigraphic.com
ISSN 0188-2198 (Print)

2016, Number S1

<< Back Next >>

Rev Mex Cardiol 2016; 27 (S1)

Experience with the use of bioactive stent coated with titanium-nitric oxide compared with zotarolimus-eluting stent in non diabetic patients with ischemic coronary heart disease: a comparative analysis and monitoring to 12 months

Córdova-Correa HG, Palacios-Rodríguez JM, García-Gutiérrez JC, Becerra-Laguna CA, García-Bonilla J, Salinas-Aragón M, López-López HA

Language: Spanish
References: 22
Page: 13-24
PDF size: 250.06 Kb.


ABSTRACT

Objective: To compare clinical outcomes in terms of frequency of mayor adverse cardiovascular events (MACE) between bioactive stent (BAS) and drug eluting stent (DES) in nondiabetic patients (pts.) with ischemic heart disease at 12-months follow-up. Material and methods: We included 529 non-diabetic patients, with ischemic cardiopathy diagnosis, who underwent percutaneous coronary interventions. For analysis, they were divided into two arms: 233 patients in the DES groups, whilst 296 in the BAS group. Results: Analysis to 12 months reported no statistically significant difference in no intervention of the lesion and/or vessel treated (TLR and TVR) between the two arms: 7.0 versus 2.6% and 2.3 versus 1.5% DES versus BAS respectively. The frequency of myocardial infarction (MI) was lower in DES 0.9 versus 1.9% BAS; p = NS. No case of stent thrombosis (ST) was observed in the DES and only 1 event in the BAS (0.33%); p = NS. Treatment of dual antigregation platelet therapy (DAPT) 3, 6 and 12 months BAS versus DES was 37.4 versus 0%, 62.6 versus 26.3%, 0 versus 73.7% respectively but with shorter periods of DAPT for BAS 7.1 ± 4.2 versus DES 11.1 ± 2.5 months; p = 0.0001. Conclusion: In this study, no differences were found in clinical outcomes at 12 months in nondiabetic patients who received DES or BAS. The overall risk of ST was very low in both groups demonstrating safety of bioactive stent in nondiabetic patients.


REFERENCES

  1. Koster R, Vieluf D Kiehn M et al. Nickel and molybdenum contact allergies in patients with coronary in stent restenosis. Lancet. 2000; 356: 1895-1897.

  2. Windecker S, Mayer I, De Pasquale G et al. Stent coating with titanium-nitride-oxide for reduction of neointimal hyperplasia. Circulation. 2001; 104: 928-933.

  3. Windecker S, Simon R, Lins M et al. Randomized comparison of a titanium-nitride-oxide coated stent with stainless steel stent for coronary revascularization. The TINOX trial. Circulation. 2005; 111: 1-6.

  4. Karjalainen PP, Ylitalo A, Niemela M et al. Two year followup after percutaneous coronary intervention with titaniumnitride-oxide-coated stent versus paclitaxel eluting stents in acute myocardial infarction. Ann Med. 2009; 41: 599-607.

  5. Karjalainen PP, Ylitalo A, Niemela M et al. Titanium-nitride-oxide coated stents versus paclitaxel eluting stents in acute myocardial infarction a 12 months follow up report from TITAX AMI trial. Eurointerv. 2008; 4: 234-241.

  6. King SB 3rd, Smith SC Jr, Hirshfeld JW Jr, Jacobs AK, Morrison DA, Williams DO, et al. 2007 Focused Update of the ACC/AHA/SCAI 2005 Guideline Update for Percutaneous Coronary Intervention: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines: 2007 Writing Group to Review New Evidence and Update the ACC/AHA/SCAI 2005 Guideline Update for Percutaneous Coronary Intervention, Writing on Behalf of the 2005 Writing Committee. Circulation. 2008; 117 (2): 261-95.

  7. Fajadet J, Wijns W, Laarman GJ, Kuck KH, Ormiston J, Münzel T et al. Randomized, double – blind , multicenter study of the endeavor zotarolimus – eluting phosphorylcholine- encapsulated stent for treatment of native coronay lesion : clinical and angiographic results of the ENDEAVOR II trial. Circulation. 2006; 114 (8): 798-806.

  8. Windecker S Mayer I, De Pasquale G et al. Stent coating with titanium .nitride oxide for reduction of neointimal hyperplasia. Circulation. 2001; 104: 928-933.

  9. Giraud-Sauveur Y on Behalf of Hexacath research and development team. EuroIntervention Publ. 2008; 526-528.

  10. Cutlip DE, Windecker S, Mehran R, Boam A, Cohen DJ, van Es G-A, Steg PG et al. Clinical end points in coronary stent trials. A case for standardized definitions. Circulation. 2007; 115: 2344-2351.

  11. Moschovitis A, Simon R, Seidenstücker A, Klauss V, Baylacher M, Lüscher TF et al. Randomized comparison of titanium-nitride-oxide coated stents with bare metal stents: five-year follow-up of the TiNOX trial. EuroIntervention. 2010; 6 (1): 63-68

  12. Mendes F, Alves L, Bastos M et al. Estudo randomizado e comparativo da intervéncao coronária percutánea com stents recobertos por titânio-óxido nítrico ou de aço inoxidável em pacientes com doença arterial coronariana:estudo RIO. Rev Bras Cardiol Invas. 2009; 17 (1): 1-7.

  13. Karjalainen PP, Ylitalo A, Niemelä M et al. Titanium-nitride-oxide coated stents versus paclitaxel eluting stents in acute myocardial infarction a 12 months follow up report from TITAX AMI trial. EuroIntervention. 2008; 4 (2): 234-241.

  14. Karjalainen PP, Ylitalo A. Niemela M et al. Two year follow-up after percutaneous coronary intervention with titaniuam-nitride-oxide- coated stent versus paclitaxel eluting stents in acute myocardial infarction. Ann Med. 2009; 41 (8): 599-607.

  15. Karjalainen PP, Ylitalo A, Airaksinen JK et al. Five-year clinical outcome of titanium-nitride-oxide-coated bioactive. Stent implantation in a real-world population: a comparison with paclitaxel-eluting stents: the PORI registry. J Interv Cardiol. 2011; 24 (1): 1-8.

  16. Valdesuso R, Karjalainen P, García J et al. The EXTREME registry: titanium-nitride-oxide coated stents in small coronary arteries. Catheter Cardiovasc Interv. 2010; 76 (2): 281-287.

  17. Karjalainen PP, Niemelä M, Airaksinen JK, Rivero-Crespo F; BACE-ACS study investigators. A prospective randomized comparison of titanium-nitride-oxide-coated bioactive stents with everolimus-eluting stents in acute coronary syndrome: the BASE-ACS trial. EuroIntervention. 2012; 8 (3): 306-315.

  18. Stone GW, Moses JW, Ellis SG et al. Safety and efficacy of sirolimus- and paclitaxel eluting coronary stents. N Engl J Med. 2007; 356: 998-1008.

  19. Limacher A, Räber L, Laube E, Lauterburg A, Lötscher S, Hess N et al. Clinical long term - term outcome after implantation of titanium nitride – oxide coated stent compared with paclitaxel - or sirolimus - eluting stents: propensity - score matchet analysis. EuroIntervention. 2012; 1043-1050.

  20. Steinhubl SR, Berger PB, Mann JT 3rd, Fry ET, DeLago A, Wilmer C. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA. 2002; 288 (19): 2411-2420.

  21. Mehta SR, Tanguay JF, Eikelboom JW et al. Double-dose versus standard-dose clopidogrel and high-dose versus low-dose aspirin in individuals undergoing percutaneous coronary intervention for acute coronary syndromes (CURRENT-OASIS 7): a randomized factorial trial. Lancet. 2010; 376 (9748): 1233-1243.

  22. Levine GN, Bates ER, Blankenship JC et al. 2011 ACCF/AHA/SCAIGuideline for Percutaneous Coronary Intervention: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions. Circulation. 2011; 124: 2574-2609.




2020     |     www.medigraphic.com